Tibet Rhodiola Pharmaceutical Holding Co (600211) — Strategic Asset Allocation Index
Tibet Rhodiola Pharmaceutical Holding Co (600211) has a Strategic Asset Allocation Index of 17.3% as of June 2023. Strategic assets (PP&E of CN¥603.61 Million plus long-term investments of CN¥-) total CN¥603.61 Million, measured against net assets of CN¥3.49 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Tibet Rhodiola Pharmaceutical Holding Co Strategic Asset Allocation Index (2000–2022)
This chart shows how Tibet Rhodiola Pharmaceutical Holding Co's Strategic Asset Allocation Index has evolved across 23 annual periods from 2000 to 2022. As of June 2023, the index stands at 17.3%, representing strategic assets of CN¥603.61 Million against net assets of CN¥3.49 Billion CNY. Explore Tibet Rhodiola Pharmaceutical Holding Co (600211) cash conversion ratio to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Tibet Rhodiola Pharmaceutical Holding Co (2000–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Tibet Rhodiola Pharmaceutical Holding Co from 2000 to 2022, covering 23 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Tibet Rhodiola Pharmaceutical Holding Co market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 18.2% | CN¥551.38 Million | CN¥551.38 Million | CN¥- | CN¥3.03 Billion | ▼ -10.7 pp |
| 2021 | 28.9% | CN¥764.54 Million | CN¥764.54 Million | CN¥- | CN¥2.65 Billion | ▲ +21.0 pp |
| 2020 | 7.9% | CN¥204.46 Million | CN¥204.46 Million | CN¥- | CN¥2.59 Billion | ▼ -3.2 pp |
| 2019 | 11.1% | CN¥271.02 Million | CN¥190.22 Million | CN¥80.81 Million | CN¥2.45 Billion | ▲ +0.7 pp |
| 2018 | 10.4% | CN¥234.64 Million | CN¥151.14 Million | CN¥83.49 Million | CN¥2.26 Billion | ▼ -2.3 pp |
| 2017 | 12.7% | CN¥260.16 Million | CN¥149.78 Million | CN¥110.38 Million | CN¥2.05 Billion | ▼ -27.3 pp |
| 2016 | 40.0% | CN¥263.10 Million | CN¥148.49 Million | CN¥114.62 Million | CN¥658.19 Million | ▲ +11.0 pp |
| 2015 | 29.0% | CN¥140.79 Million | CN¥106.56 Million | CN¥34.24 Million | CN¥485.90 Million | ▲ +2.7 pp |
| 2014 | 26.3% | CN¥108.81 Million | CN¥108.81 Million | CN¥- | CN¥414.18 Million | ▼ -1.7 pp |
| 2013 | 28.0% | CN¥111.74 Million | CN¥111.74 Million | CN¥- | CN¥399.20 Million | ▲ +1.5 pp |
| 2012 | 26.5% | CN¥102.02 Million | CN¥102.02 Million | CN¥- | CN¥385.44 Million | ▲ +0.5 pp |
| 2011 | 26.0% | CN¥92.17 Million | CN¥92.17 Million | CN¥- | CN¥354.94 Million | ▼ -3.8 pp |
| 2010 | 29.8% | CN¥96.54 Million | CN¥96.54 Million | CN¥- | CN¥324.19 Million | ▼ -4.1 pp |
| 2009 | 33.8% | CN¥101.54 Million | CN¥101.54 Million | CN¥- | CN¥300.00 Million | ▼ -0.3 pp |
| 2008 | 34.2% | CN¥95.39 Million | CN¥95.39 Million | CN¥- | CN¥279.15 Million | ▼ -36.6 pp |
| 2007 | 70.8% | CN¥194.09 Million | CN¥194.09 Million | CN¥- | CN¥274.28 Million | ▲ +7.8 pp |
| 2006 | 62.9% | CN¥249.44 Million | CN¥249.44 Million | CN¥- | CN¥396.34 Million | ▼ -2.2 pp |
| 2005 | 65.1% | CN¥256.18 Million | CN¥256.18 Million | CN¥- | CN¥393.25 Million | ▼ -2.4 pp |
| 2004 | 67.5% | CN¥294.11 Million | CN¥294.11 Million | CN¥- | CN¥435.51 Million | ▲ +1.3 pp |
| 2003 | 66.3% | CN¥281.25 Million | CN¥281.25 Million | CN¥- | CN¥424.53 Million | ▲ +2.4 pp |
| 2002 | 63.9% | CN¥267.61 Million | CN¥267.61 Million | CN¥- | CN¥418.85 Million | ▲ +5.0 pp |
| 2001 | 58.9% | CN¥239.29 Million | CN¥239.29 Million | CN¥- | CN¥406.50 Million | ▼ -3.9 pp |
| 2000 | 62.8% | CN¥252.51 Million | CN¥252.51 Million | CN¥- | CN¥402.35 Million | — |